| Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial L Saiman, BC Marshall, N Mayer-Hamblett, JL Burns, AL Quittner, ... Jama 290 (13), 1749-1756, 2003 | 1234 | 2003 |
| The future of cystic fibrosis care: a global perspective SC Bell, MA Mall, H Gutierrez, M Macek, S Madge, JC Davies, PR Burgel, ... The Lancet Respiratory Medicine 8 (1), 65-124, 2020 | 955 | 2020 |
| Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation FJ Accurso, SM Rowe, JP Clancy, MP Boyle, JM Dunitz, PR Durie, ... New England Journal of Medicine 363 (21), 1991-2003, 2010 | 950 | 2010 |
| Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... American journal of respiratory and critical care medicine 190 (2), 175-184, 2014 | 552 | 2014 |
| Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial L Saiman, M Anstead, N Mayer-Hamblett, LC Lands, M Kloster, ... Jama 303 (17), 1707-1715, 2010 | 395 | 2010 |
| Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis AL Smith, SB Fiel, N Mayer-Hamblett, B Ramsey, JL Burns Chest 123 (5), 1495-1502, 2003 | 347 | 2003 |
| Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR … MW Konstan, EF McKone, RB Moss, G Marigowda, S Tian, D Waltz, ... The lancet Respiratory medicine 5 (2), 107-118, 2017 | 331 | 2017 |
| Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality N Mayer-Hamblett, M Rosenfeld, J Emerson, CH Goss, ML Aitken American journal of respiratory and critical care medicine 166 (12), 1550-1555, 2002 | 316 | 2002 |
| Residual weighted learning for estimating individualized treatment rules X Zhou, N Mayer-Hamblett, U Khan, MR Kosorok Journal of the American Statistical Association 112 (517), 169-187, 2017 | 294 | 2017 |
| Association between pulmonary function and sputum biomarkers in cystic fibrosis N Mayer-Hamblett, ML Aitken, FJ Accurso, RA Kronmal, MW Konstan, ... American journal of respiratory and critical care medicine 175 (8), 822-828, 2007 | 283 | 2007 |
| LasR variant cystic fibrosis isolates reveal an adaptable quorum-sensing hierarchy in Pseudomonas aeruginosa JB Feltner, DJ Wolter, CE Pope, MC Groleau, NE Smalley, EP Greenberg, ... MBio 7 (5), 10.1128/mbio. 01513-16, 2016 | 253 | 2016 |
| Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis MM Treggiari, G Retsch-Bogart, N Mayer-Hamblett, U Khan, M Kulich, ... Archives of pediatrics & adolescent medicine 165 (9), 847-856, 2011 | 251 | 2011 |
| Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor SL Heltshe, N Mayer-Hamblett, JL Burns, U Khan, A Baines, BW Ramsey, ... Clinical infectious diseases 60 (5), 703-712, 2015 | 234 | 2015 |
| Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications MA Mall, N Mayer-Hamblett, SM Rowe American journal of respiratory and critical care medicine 201 (10), 1193-1208, 2020 | 204 | 2020 |
| Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis CL Ordoñez, NR Henig, N Mayer-Hamblett, FJ Accurso, JL Burns, ... American journal of respiratory and critical care medicine 168 (12), 1471-1475, 2003 | 203 | 2003 |
| Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis CH Goss, N Mayer-Hamblett, ML Aitken, GD Rubenfeld, BW Ramsey Thorax 59 (11), 955-959, 2004 | 183 | 2004 |
| Pulmonary complications of cystic fibrosis PA Flume Respiratory care 54 (5), 618-627, 2009 | 170* | 2009 |
| Microbiology of cystic fibrosis airway disease AC Blanchard, VJ Waters Seminars in respiratory and critical care medicine 40 (06), 727-736, 2019 | 169 | 2019 |
| Risk factors for first cerebrospinal fluid shunt infection: findings from a multi-center prospective cohort study TD Simon, J Butler, KB Whitlock, SR Browd, R Holubkov, JRW Kestle, ... The Journal of pediatrics 164 (6), 1462-1468. e2, 2014 | 169 | 2014 |
| Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher R Szczesniak, SL Heltshe, S Stanojevic, N Mayer-Hamblett Journal of Cystic Fibrosis 16 (3), 318-326, 2017 | 152 | 2017 |